NO993945L - Disubstituted bicyclic heterocycles, their preparation and use as drugs - Google Patents

Disubstituted bicyclic heterocycles, their preparation and use as drugs

Info

Publication number
NO993945L
NO993945L NO993945A NO993945A NO993945L NO 993945 L NO993945 L NO 993945L NO 993945 A NO993945 A NO 993945A NO 993945 A NO993945 A NO 993945A NO 993945 L NO993945 L NO 993945L
Authority
NO
Norway
Prior art keywords
drugs
preparation
bicyclic heterocycles
disubstituted bicyclic
disubstituted
Prior art date
Application number
NO993945A
Other languages
Norwegian (no)
Other versions
NO313879B1 (en
NO993945D0 (en
Inventor
Norbert Hauel
Uwe Ries
Henning Priepke
Wolfgang Wienen
Jean Marie Stassen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26034058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO993945(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19706229A external-priority patent/DE19706229A1/en
Priority claimed from DE1997151939 external-priority patent/DE19751939A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO993945D0 publication Critical patent/NO993945D0/en
Publication of NO993945L publication Critical patent/NO993945L/en
Publication of NO313879B1 publication Critical patent/NO313879B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
NO19993945A 1997-02-18 1999-08-17 Disubstituted bicyclic heterocycles, use and preparation thereof and drug NO313879B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19706229A DE19706229A1 (en) 1997-02-18 1997-02-18 New aryl-substituted bi:cyclic heterocyclic compounds
DE1997151939 DE19751939A1 (en) 1997-11-24 1997-11-24 New aryl-substituted bi:cyclic heterocyclic compounds
PCT/EP1998/000865 WO1998037075A1 (en) 1997-02-18 1998-02-16 Disubstituted bicyclic heterocycles, their production and use as medicaments

Publications (3)

Publication Number Publication Date
NO993945D0 NO993945D0 (en) 1999-08-17
NO993945L true NO993945L (en) 1999-10-15
NO313879B1 NO313879B1 (en) 2002-12-16

Family

ID=26034058

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19993945A NO313879B1 (en) 1997-02-18 1999-08-17 Disubstituted bicyclic heterocycles, use and preparation thereof and drug
NO2008012C NO2008012I2 (en) 1997-02-18 2008-07-31 Dabigatran ethoxylate and its salts - especially dabigatran ethoxylate mesylate
NO2021005C NO2021005I1 (en) 1997-02-18 2021-02-05 Pradaxa - Dabigatran etexilate mesilate - extended SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2008012C NO2008012I2 (en) 1997-02-18 2008-07-31 Dabigatran ethoxylate and its salts - especially dabigatran ethoxylate mesylate
NO2021005C NO2021005I1 (en) 1997-02-18 2021-02-05 Pradaxa - Dabigatran etexilate mesilate - extended SPC

Country Status (39)

Country Link
EP (1) EP0966454B1 (en)
JP (1) JP3343359B2 (en)
KR (1) KR100619458B1 (en)
CN (1) CN1088702C (en)
AR (1) AR010896A1 (en)
AT (1) ATE239712T1 (en)
AU (1) AU742593C (en)
BG (1) BG64558B1 (en)
BR (1) BR9807843B1 (en)
CA (1) CA2277949C (en)
CO (1) CO4920237A1 (en)
CZ (1) CZ297768B6 (en)
DE (2) DE122008000020I1 (en)
DK (1) DK0966454T3 (en)
EA (1) EA003697B1 (en)
EE (1) EE04716B1 (en)
EG (1) EG24144A (en)
ES (1) ES2199426T4 (en)
FR (1) FR08C0025I2 (en)
HK (1) HK1025096A1 (en)
HR (1) HRP980082B1 (en)
HU (1) HU223754B1 (en)
IL (1) IL130812A (en)
LT (1) LTC0966454I2 (en)
LU (1) LU91437I2 (en)
MY (1) MY129408A (en)
NL (1) NL300349I2 (en)
NO (3) NO313879B1 (en)
NZ (1) NZ337323A (en)
PE (1) PE121699A1 (en)
PL (1) PL195551B1 (en)
PT (1) PT966454E (en)
RS (1) RS49686B (en)
SA (1) SA98190047B1 (en)
SI (1) SI0966454T1 (en)
SK (1) SK285432B6 (en)
TR (1) TR199902017T2 (en)
TW (1) TW588047B (en)
WO (1) WO1998037075A1 (en)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026933A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
AU2720199A (en) * 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
EP1054886B1 (en) * 1998-02-09 2002-09-04 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
US6248770B1 (en) 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
JP2002536446A (en) * 1999-02-09 2002-10-29 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド Heteroarylamidines, methylamidines and guanidines as protease inhibitors
DE19907813A1 (en) * 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituted bicyclic heterocycles, their preparation and their use as pharmaceuticals
AR023510A1 (en) 1999-04-21 2002-09-04 Astrazeneca Ab A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR.
DE19939463A1 (en) * 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides
US6512000B1 (en) 1999-08-20 2003-01-28 Boehringer Ingelheim Pharma Kg Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity
DE19945810A1 (en) * 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma Substituted benzimidazole derivatives, process for their preparation and their use as medicaments
DE50001742D1 (en) * 1999-09-24 2003-05-15 Boehringer Ingelheim Pharma ARYLSULFONAMIDE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS
US6413990B1 (en) 1999-09-24 2002-07-02 Boehringer Ingelheim Pharma Kg Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity
DE19945787A1 (en) 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma New 2-(amidino- or aminomethyl-phenethyl)-5-sulfonylamino-benzimidazoles, are tryptase inhibitors useful e.g. for treating inflammatory or allergic disease such as asthma, urticaria or arthritis
US6407130B1 (en) 1999-11-10 2002-06-18 Boehringer Ingelheim Pharma Kg Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity
US6451832B2 (en) 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
BR0208985A (en) * 2001-04-19 2004-03-09 Eisai Co Ltd 2-iminopyrrolidine derivatives
DE10133786A1 (en) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Use of thrombin inhibitors for the treatment of arthritis
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP1485094B2 (en) * 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Dosage form for oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester or its salts
DE10235639A1 (en) 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New prodrugs of benzimidazole-5-carboxamide derivative thrombin inhibitor, useful for treating or preventing thrombotic diseases, are well tolerated on subcutaneous injection
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
PE20040804A1 (en) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR
DE10260730A1 (en) 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted nitrogen-containing heterobicyclene, their preparation and their use as pharmaceuticals
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
JP4549970B2 (en) 2003-02-19 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing cyclic benzamidine derivative
DE10310278A1 (en) * 2003-03-10 2004-09-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New N-(benzazinyl)-(hetero)aralkylamine derivatives, are inhibitors of factor Xa and/or related serine proteases, useful e.g. as antithrombotic agents and intermediates
CN1812792A (en) 2003-04-24 2006-08-02 贝林格尔.英格海姆国际有限公司 Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
CN1832920A (en) 2003-08-08 2006-09-13 特兰斯泰克制药公司 Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
DE10337697A1 (en) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
DE10339862A1 (en) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
DE10341043A1 (en) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Oral Dosage Form for 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] Propionic acid ethyl ester and its salts
EP1609784A1 (en) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (en) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke
DE102005025728A1 (en) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102005061624A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines
DE102005061623A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts
US8044242B2 (en) 2006-03-09 2011-10-25 Bristol-Myers Squibb Company 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants
JP2009539873A (en) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 2-Aminocarbonylphenylamino-2-phenylacetamides as Factor Vila inhibitors useful as anticoagulants
WO2008009639A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
CL2007002068A1 (en) * 2006-07-17 2008-01-18 Boehringer Ingelheim Int Use of dabigatran, dabigatran ethoxylate, (n-2-pyridyl-n-2-ethoxycarbonylethyl) amide of 1-methyl-2- [4- (n-hydroxyamidino) phenylaminoethyl] benzimidazol-5-yl-carboxylic acid, melagatran, ximelagatran, hirudin, hirulog and argatroban for the treatment of cerebral infarction, myocardial infarction, thrombosis, pulmonary embolism, among others.
JP2010505906A (en) * 2006-10-10 2010-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 3-[(2-{[4- (Hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazol-5-carbonyl) -pyridin-2-yl-amino] -Physiologically acceptable salt of propionic acid ethyl ester
JP5342450B2 (en) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー Arylpropionamide, arylacrylamide, arylpropinamide, or arylmethylurea analogs as factor XIa inhibitors
PE20081775A1 (en) 2006-12-20 2008-12-18 Bristol Myers Squibb Co MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
EP1956018A1 (en) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Method of preparing a derivative of benzimidazole
MY153427A (en) 2007-04-23 2015-02-13 Sanofi Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
WO2009018405A1 (en) * 2007-07-31 2009-02-05 Mallinckrodt Inc. Integrated photoactive agents and uses thereof
JP5504171B2 (en) 2007-12-26 2014-05-28 サノフイ Heterocyclic pyrazole-carboxamides as P2Y12 antagonists
CZ305085B6 (en) * 2008-03-14 2015-04-29 Zentiva, K.S. Process for preparing dabigatran
NZ589746A (en) * 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
US20110190352A1 (en) * 2008-08-19 2011-08-04 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
CZ2008669A3 (en) * 2008-10-24 2010-05-05 Zentiva, A. S. Process for preparing dabigatran and intermediates thereof
BRPI1007934B1 (en) 2009-02-02 2021-08-31 Boehringer Ingelheim International Gmbh COMPOSITION OF LYOPHILLED DABIGATRANA, ITS MANUFACTURING, USE, TEST AND KIT PROCESS
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
JP2013502449A (en) 2009-08-24 2013-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Emergency treatment of activated carbon by overdose of dabigatran etexilate
CN102050814B (en) * 2009-11-06 2014-05-28 北京美倍他药物研究有限公司 Ester derivatives of dabigatran
CN102050815B (en) * 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
TWI513466B (en) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int Anticoagulant antidotes
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
ES2674745T3 (en) 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrocycles as inhibitors of factor XIa
WO2011107427A1 (en) 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
JP2013521318A (en) 2010-03-08 2013-06-10 ラティオファルム ゲー・エム・ベー・ハー Pharmaceutical composition containing dabigatran etexilate
EP2588090B2 (en) 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012004396A2 (en) 2010-07-09 2012-01-12 Esteve Química, S.A. Process of preparing a thrombin specific inhibitor
WO2012004397A1 (en) 2010-07-09 2012-01-12 Esteve Química, S.A. Intermediates and process for preparing a thrombin specific inhibitor
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
KR20140009437A (en) 2011-03-30 2014-01-22 베링거 인겔하임 인터내셔날 게엠베하 Anticoagulant antidotes
HUP1100244A2 (en) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Pharmaceutical intermediates and process for their production
CN102250099B (en) * 2011-05-16 2013-10-16 中国药科大学 Non-peptide thrombin inhibitors as well as preparation method and medical application thereof
CN102838588B (en) * 2011-06-24 2014-03-19 中国药科大学 Oral thrombin inhibitors, preparation methods and medical uses thereof
SI2550966T1 (en) * 2011-07-25 2017-01-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Amidoxime carboxylic acid esters of dabigatran as prodrugs and their use as medicament
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
WO2013024394A1 (en) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited Novel reference markers of dabigatran etexilate
CN102993174A (en) * 2011-09-08 2013-03-27 天津药物研究院 Dabigatran etexilate derivative as a prodrug
CN102993175B (en) * 2011-09-08 2014-08-13 天津药物研究院 Dabigatran derivatives, and preparation method and application thereof
AR088456A1 (en) 2011-10-14 2014-06-11 Bristol Myers Squibb Co TETRAHYDROISOQUINOLINE COMPOUNDS REPLACED AS INHIBITORS OF THE XIA FACTOR
IN2014CN02805A (en) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
MX2014007331A (en) 2011-12-22 2014-09-01 Boehringer Ingelheim Int Immediate release multi unit pellet system.
WO2013111163A2 (en) 2012-01-20 2013-08-01 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
JP2015504903A (en) 2012-01-24 2015-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New dabigatran formulation for oral administration
KR102090242B1 (en) 2012-02-21 2020-03-18 에스테베 파마슈티칼스 에스에이 Oral pharmaceutical compositions of dabigatran etexilate
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN103387566B (en) * 2012-05-09 2015-09-09 上海医药工业研究院 Prepare the method for 3-[[[2-[[(4-cyano-phenyl) is amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-base] carbonyl] (pyridine-2-base) is amino] ethyl propionate
CN103420980A (en) * 2012-05-22 2013-12-04 北京美倍他药物研究有限公司 Dabigatran derivatives
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
WO2014012880A1 (en) 2012-07-16 2014-01-23 Interquim, S.A. Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates
CN102766134B (en) * 2012-07-19 2014-06-25 北京普禄德医药科技有限公司 Dabigatran etexilate derivative and preparation method and application thereof
WO2014021383A1 (en) 2012-07-31 2014-02-06 協和発酵キリン株式会社 Condensed ring heterocyclic compound
KR20150038369A (en) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 Dihydropyridone p1 as factor xia inhibitors
KR20150038372A (en) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 Dihydropyridone p1 as factor xia inhibitors
WO2014041559A2 (en) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of dabigatran etexilate and intermediates thereof
WO2014060545A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of dabigatran free base
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
US9533971B2 (en) 2012-10-29 2017-01-03 Biophore India Pharmaceuticals Pvt. Ltd Process for the synthesis of dabigatran and its intermediates
US10077251B2 (en) 2012-10-29 2018-09-18 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of Dabigatran Etexilate and its intermediates
CN102977077A (en) * 2012-11-28 2013-03-20 浙江燎原药业有限公司 Method for preparing dabigatran etexilate intermediate
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103044404A (en) * 2013-01-14 2013-04-17 中国药科大学 Dabigatran derivatives, and preparation method and application thereof in antithrombosis
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
CN103224469A (en) * 2013-05-16 2013-07-31 上海应用技术学院 Pradaxa analogue with fluorine-containing group modified benzene ring as center and synthesis method thereof
WO2014195230A1 (en) 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted benzoxazoles
UY35592A (en) * 2013-06-03 2014-12-31 Bayer Pharma AG BENZOXAZOLES REPLACED
CN103288744A (en) * 2013-06-04 2013-09-11 上海应用技术学院 Fluorine group-containing-modified dabigatran etexilate analogue and synthetic method thereof
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
NO2760821T3 (en) 2014-01-31 2018-03-10
US9777001B2 (en) 2014-01-31 2017-10-03 Bristol-Myers Squibb Company Macrocycles with aromatic P2′ groups as factor xia inhibitors
WO2015128875A2 (en) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015137680A1 (en) * 2014-03-10 2015-09-17 동아에스티 주식회사 Pharmaceutical composition for treating or preventing stroke and systemic embolism
IN2014MU01042A (en) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
CN104230888A (en) * 2014-06-03 2014-12-24 长春工业大学 Preparation method of benzimidazole compound
CN105218519A (en) * 2014-06-04 2016-01-06 天津药物研究院 A kind of preparation method of dabigatran etexilate intermediate
CN104003977B (en) * 2014-06-05 2016-04-13 雅本化学股份有限公司 The preparation method of N-(2-chloromethyl-1-methyl isophthalic acid H-benzoglyoxaline-5-acyl group)-N-(pyridine-2-base)-3-alanine ethyl ester
DE102014108210A1 (en) 2014-06-11 2015-12-17 Dietrich Gulba rodenticide
CN104045628B (en) * 2014-06-13 2019-04-09 深圳翰宇药业股份有限公司 The purification process of benzimidizole derivatives
CN105315257A (en) * 2014-06-24 2016-02-10 华仁药业股份有限公司 Synthetic and purifying method of dabigatran etexilate
WO2016019848A1 (en) * 2014-08-06 2016-02-11 四川海思科制药有限公司 Dabigatran thioester derivative, preparation method therefor, and pharmaceutical use thereof
WO2016019849A1 (en) * 2014-08-06 2016-02-11 四川海思科制药有限公司 Dabigatran carboalkoxy derivative, preparation method therefor, and pharmaceutical use thereof
NO2721243T3 (en) 2014-10-01 2018-10-20
US10675276B2 (en) 2014-11-03 2020-06-09 Hangzhou Solipharma Co., Ltd. Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof
CN104592204B (en) * 2014-12-26 2017-05-17 华润赛科药业有限责任公司 Dabigatran derivatives as well as preparation method and application thereof
CN104650037A (en) * 2014-12-30 2015-05-27 青岛黄海制药有限责任公司 Synthesis method of dabigatran etexilate
TR201502223A2 (en) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dronedarone and dabigatran
CN104628733A (en) * 2015-03-02 2015-05-20 中国药科大学 Tetrahydrobenzo[4,5] imidazo[1,2-a] pyrazine thrombin inhibitors
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
CN104987323B (en) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 A kind of preparation method of dabigatran etcxilate
EP3324946A1 (en) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations of dabigatran free base
CN107922393A (en) 2015-07-29 2018-04-17 百时美施贵宝公司 Carry non-aromatic P2,The new big rings of the factor XI, plasma thromboplastin antecedent A of group
JP6785838B2 (en) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ FXIA inhibitor of novel substitution glycine induction
CN105294651A (en) * 2015-09-23 2016-02-03 烟台东诚药业集团股份有限公司 Method for synthesizing and preparing pradaxa formamidine intermediates
CN106866626A (en) * 2015-12-14 2017-06-20 天津药物研究院有限公司 A kind of preparation method of dabigatran etexilate intermediate
CN105481831B (en) * 2015-12-16 2018-06-12 开封明仁药业有限公司 A kind of method for preparing dabigatran etexilate intermediate
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
CN105566297A (en) * 2015-12-31 2016-05-11 哈药集团技术中心 Preparation method of dabigatran etexilate mesylate
WO2017151746A1 (en) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
CN105669651B (en) * 2016-03-07 2018-03-06 山东罗欣药业集团股份有限公司 A kind of preparation technology of dabigatran etexilate methanesulfonate
CN106397400A (en) * 2016-04-14 2017-02-15 江苏康缘药业股份有限公司 Preparation method for dabigatran etexilate
TR201606697A2 (en) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi NEW ORAL PHARMACEUTICAL FORMULATIONS OF DABIGATRA
CN106349221A (en) * 2016-08-29 2017-01-25 常州市阳光药业有限公司 Preparation method of high-purity dabigatran etexilate
TR201617984A2 (en) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN
WO2018104387A1 (en) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayered tablet compositions of dabigatran
JP2018184375A (en) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same
TR201706848A2 (en) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE
WO2019004980A2 (en) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
CN109010249A (en) * 2017-06-08 2018-12-18 上海美悦生物科技发展有限公司 Injection dabigatran etcxilate pharmaceutical composition and its preparation method and application
KR20190036857A (en) 2017-09-28 2019-04-05 한미약품 주식회사 Composite capsule formulation comprising dabigatran etexilate
TR201722186A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of dabigatran
TR201722323A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions of dabigatran
TR201722630A2 (en) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
WO2019196111A1 (en) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 Anti-tumor multidrug resistance of heteroaryl amide compound, use in treatment of cancers and protein-drug molecular complex
CN108864047A (en) * 2018-07-02 2018-11-23 河南师范大学 A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN111606885A (en) * 2020-06-18 2020-09-01 安徽鼎旺医药有限公司 Dabigatran etexilate mesylate and preparation method thereof
CN113929661A (en) * 2020-06-29 2022-01-14 石药集团恩必普药业有限公司 Dabigatran etexilate intermediate and preparation method thereof
EP4070658A1 (en) 2021-04-06 2022-10-12 BIORoxx GmbH Use of anticoagulant active compounds as rodenticide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675405A (en) * 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
CA2134192A1 (en) * 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists

Also Published As

Publication number Publication date
AU742593C (en) 2004-04-29
BR9807843A (en) 2001-06-19
BG103655A (en) 2000-02-29
CZ297768B6 (en) 2007-03-28
EP0966454A1 (en) 1999-12-29
NO2008012I2 (en) 2010-05-25
TW588047B (en) 2004-05-21
CZ291599A3 (en) 2000-06-14
HRP980082A2 (en) 1998-10-31
JP3343359B2 (en) 2002-11-11
BG64558B1 (en) 2005-07-29
EA199900746A1 (en) 2000-08-28
CO4920237A1 (en) 2000-05-29
MY129408A (en) 2007-03-30
NO313879B1 (en) 2002-12-16
DE59808281D1 (en) 2003-06-12
FR08C0025I2 (en) 2009-11-20
EE9900359A (en) 2000-02-15
SA98190047B1 (en) 2005-12-12
NL300349I1 (en) 2008-08-01
EA003697B1 (en) 2003-08-28
HRP980082B1 (en) 2003-08-31
EP0966454B1 (en) 2003-05-07
KR20000071066A (en) 2000-11-25
TR199902017T2 (en) 1999-10-21
EG24144A (en) 2008-08-06
NO2021005I1 (en) 2021-02-05
RS49686B (en) 2007-12-31
SK285432B6 (en) 2007-01-04
DE122008000020I1 (en) 2008-08-07
FR08C0025I1 (en) 2008-07-18
WO1998037075A1 (en) 1998-08-27
PL335154A1 (en) 2000-04-10
KR100619458B1 (en) 2006-09-08
PE121699A1 (en) 1999-12-08
AR010896A1 (en) 2000-07-12
NL300349I2 (en) 2008-10-01
NO993945D0 (en) 1999-08-17
HUP0001116A3 (en) 2001-07-30
NO2008012I1 (en) 2008-08-25
LTC0966454I2 (en) 2021-08-10
SI0966454T1 (en) 2003-10-31
NZ337323A (en) 2000-11-24
HUP0001116A2 (en) 2001-05-28
LU91437I2 (en) 2008-07-14
ES2199426T3 (en) 2004-02-16
AU6399198A (en) 1998-09-09
BR9807843B1 (en) 2010-06-29
PL195551B1 (en) 2007-10-31
YU38799A (en) 2001-03-07
IL130812A0 (en) 2001-01-28
CN1248251A (en) 2000-03-22
CA2277949C (en) 2006-10-03
JP2001509815A (en) 2001-07-24
DK0966454T3 (en) 2003-09-01
CA2277949A1 (en) 1998-08-27
ES2199426T4 (en) 2007-08-16
PT966454E (en) 2003-09-30
ATE239712T1 (en) 2003-05-15
HK1025096A1 (en) 2000-11-03
IL130812A (en) 2005-12-18
LTPA2008008I1 (en) 2021-02-25
HU223754B1 (en) 2005-01-28
LU91437I9 (en) 2019-01-02
AU742593B2 (en) 2002-01-10
CN1088702C (en) 2002-08-07
SK112199A3 (en) 2000-05-16
EE04716B1 (en) 2006-10-16

Similar Documents

Publication Publication Date Title
DK0966454T3 (en) Disubstituted bicyclic heterocycles, their preparation and their use as drugs
NO991815D0 (en) Oxadiazoles, processes for their preparation and their use as drugs
PT911340E (en) SUBSTITUTED ISOKINOLINES-3-CARBOXAMIDES, ITS PREPARATION AND USE AS DRUGS
NO20011503D0 (en) Indeno-, naphtho- and benzocyclohepta-dihydrotiazole derivatives, their preparation and use as anorectic drugs
DK1095025T3 (en) Benzimidazoles, their preparation and their use as drugs
NO20005146L (en) Thienylazolylalkoxyethanamines, their preparation and their use as drugs
DK0869126T3 (en) Dithioland derivatives, their preparation and their therapeutic effect
DK1083171T3 (en) Pyrazoline derivatives, their preparation and use as drugs
DK1112251T3 (en) Acetidine derivatives, their preparation and drugs containing these derivatives
NO993003L (en) Sulfonamide derivatives, processes for their preparation and their use as medicaments
NO20011216L (en) Acetidine derivatives, their preparation and medicaments containing the compounds
NO20006138D0 (en) Substituted indolinones, preparation and use thereof as drugs
NO971811D0 (en) Bicyclic tetrahydropyrazolopyridines and their use as drugs
NO985368D0 (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations containing the compounds
NO20000294L (en) Derivatives of acylpiperazinylpyrimidines, their preparation and use as pharmaceuticals
EE04497B1 (en) Pyridopyranoazepine derivatives, their preparation and therapeutic use
NO20022021D0 (en) Indeno-, naphtho- and benzocyclohepta-dihydrotiazole derivatives, the preparation of the same and their use as anorexic drugs
NO307510B1 (en) Bicyclic aromatic compounds, their use and pharmaceutical and cosmetic preparations thereof
NO20016247D0 (en) Streptogramin derivatives, their preparation and preparations containing the derivatives
NO20001934D0 (en) 3-Substituted tetrahydropyridopyrimidinone derivatives, their preparation and use
NO983472D0 (en) Taxoids, their preparation and pharmaceutical preparations containing the taxoids
NO308213B1 (en) Substituted indanylidinacetylguanidines, their use and drugs containing the compounds
NO20000066D0 (en) 6-Pyrrolidin-2-ylpyrindine Derivatives, their Preparation and their Pharmaceutical Use
NO20015617L (en) Spiroimidazole derivatives, their preparation, their use and pharmaceutical preparations including such derivatives
NO20022457L (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as drugs

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PRADAXA-DABIGATRANETEXILAT; NAT. REG. NO/DATE: EU108442001-008/NO 20080414; FIRST REG. NO/DATE: EU , EU108442001-008 20080318

Spc suppl protection certif: 2008012

Filing date: 20080731

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: PRADAXA-DABIGATRANETEXILAT; NAT. REG. NO/DATE: EU108442001-008/NO 20080414; FIRST REG. NO/DATE: EU , EU108442001-008 20080318

Spc suppl protection certif: 2008012

Filing date: 20080731

Extension date: 20230216

MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PRADAXA - DABIGATRANETEXILATMESILAT - FORLENGET SPC; REG. NO/DATE: EU108442001-008/NO 20080414

Spc suppl protection certif: 2021005

Filing date: 20210205

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: PRADAXA - DABIGATRANETEXILATMESILAT - FORLENGET SPC; REG. NO/DATE: EU108442001-008/NO 20080318

Spc suppl protection certif: 2021005

Filing date: 20210205

Extension date: 20230816

SPCX Expiry of an spc

Spc suppl protection certif: 2021005